Detalhe da pesquisa
1.
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
BioDrugs
; 35(4): 429-444, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33914256
2.
Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study.
Lung Cancer Manag
; 8(3): LMT15, 2019 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31807143